Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study will compare the effects of treatment with nivolumab alone versus those of
nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink
the cancer or prevent it from returning, but it could also cause side effects.